An overview of current and emerging devices for percutaneous left atrial appendage closure.


Journal

Trends in cardiovascular medicine
ISSN: 1873-2615
Titre abrégé: Trends Cardiovasc Med
Pays: United States
ID NLM: 9108337

Informations de publication

Date de publication:
05 2019
Historique:
received: 16 05 2018
revised: 30 07 2018
accepted: 18 08 2018
pubmed: 13 9 2018
medline: 29 5 2019
entrez: 13 9 2018
Statut: ppublish

Résumé

Atrial fibrillation (AF) is common and is a prominent risk factor for ischemic stroke. Oral anticoagulant (OAC) therapy has been the main strategy for stroke prevention in AF patients; however, OAC therapy carries a bleeding risk and is not tolerated by all patients. Left atrial appendage (LAA) closure offers a non-pharmacological alternative for stroke prevention in patients with non-valvular AF. In this update, an overview of current and emerging LAA occluders is given - with special attention to the key design features of every single device and, if available, preclinical or clinical data.

Identifiants

pubmed: 30205924
pii: S1050-1738(18)30174-9
doi: 10.1016/j.tcm.2018.08.008
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

228-236

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Danny H F Chow (DHF)

The Heart Center, Rigshospitalet, Copenhagen, Denmark.

Yam-Hong Wong (YH)

The Heart Center, Rigshospitalet, Copenhagen, Denmark; Medicine and Geriatrics, Tuen Mun Hospital, Hong Kong.

Jai-Wun Park (JW)

Charite University Hospital, Berlin, Germany.

Yat-Yin Lam (YY)

Wuhan University of Science and Technology, Wuhan, China.

Tom De Potter (T)

OLV Cardiac Center, Aalst, Belgium.

Josep Rodés-Cabau (J)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Lluis Asmarats (L)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Marcus Sandri (M)

Heart Center University Hospital, Cardiology Division, Leipzig, Germany.

Eleftherios Sideris (E)

The Athenian Institute of Pediatric Cardiology, Athens, Greece.

Trevor McCaw (T)

Aegis Medical Innovations, Vancouver, Canada.

Randall J Lee (RJ)

Cardiovascular Research Institute, University of California San Francisco, San Francisco, USA.

Horst Sievert (H)

Anglia Ruskin University, Chelmsford, UK; CardioVascular Center Frankfurt CVC, Frankfurt, Germany; University California, San Francisco, USA; Yunnan Hospital Fuwai, Kunming, China.

Lars Søndergaard (L)

The Heart Center, Rigshospitalet, Copenhagen, Denmark.

Ole De Backer (O)

The Heart Center, Rigshospitalet, Copenhagen, Denmark. Electronic address: ole.debacker@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH